• Accession: P05231
  • Swissprot: IL6_HUMAN
  • Organism: Homo sapiens
  • Gene: IL6
  • Target class: Cytokine

Drug Relations:

a chimeric anti-interleukin-6 antibody for treatment of multiple myeloma and renal cell carcinoma; in phase I and phase II clinical trials. It was investigated for its potential to combat cytokine release syndrome (CRS) in patients with severely ill COVID-19 but the efficacy and safety of siltuximab in the treatment of COVID-19 were not established. Bioactivity details MOA
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Bioactivity details MOA
A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue. Bioactivity details MOA